Home
About Us
Membership
Member Biography

Member Biography

Shadia I. Jalal, MD

Shadia I. Jalal, M.D.

Phone: (317) 944-0920
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
RT473
Indianapolis, IN 46202

Faculty appointments

Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Lawrence H. Einhorn Scholar in Oncology, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Full member, Experimental and Developmental Therapeutics

Specialized in esophageal and lung cancer. Clinical interest is in thoracic oncology and the management of all forms of lung cancer. Basic science interest is focused on the study of DNA repair capacity and its impact on patient response to chemotherapy in hopes of personalizing therapy.I have a lab where I conduct this research. I see patients in our multidisciplinary thoracic oncology clinic.I am an active member of the lung cancer working group.

A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction AdenocarcinomaCTO-EA2174

A pilot study evaluating the feasibility and safety of a fasting-mimicking diet in patients receiving systemic treatment for metastatic non-small cell lung cancerIUSCC-0662

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersEA5142

A Biomarker-Driven Protocol for Previously Treated ALK-Positive NSCLC Patients: The NCI-NRG ALK Master ProtocolNRG-LU003

Rapid ( Warm ) Autopsy Protocol for Patients with Small Cell Lung CancerCTO-IUSCCC-0783

A Pilot Study Evaluating a Novel Biodynamic Imaging (BDI) Method in Predicating Response to Chemotherapy in Locoregional Esophageal CancerIUCRO-0486

Circulating Tumor Cells (CTC) in Lung CancerCTO-IUSCC-0567

A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinE4512

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)A151216

RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)A081105

A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)CTO-EA2183

A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric CancerCTO-HLX22-GC-301

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positiveCTO-8951-CL-0305

Headlines & highlights

Simon Says Expert Series featuring Shadia Jalal

Esophageal Cancer Awareness: Gastroesophageal Reflux, Cancer & More

April 2023

Lung Cancer Screening: A Decade of Advances, Challenges and Opportunities

November 2022

#ResearchCuresCancer

Support Our Research